|
SenzaGen has had another dynamic and successful year in 2023, actively advancing our vision of replacing animal testing with innovative methods that more accurately reflect human biology. Below is a snapshot of key events from this year. |
|
|
|
|
SenzaGen was recently selected to test substances for yet another new customer, a global industry leader. The assignment comprises non-animal tests for skin sensitization, including SenzaGen’s highly performing test platform, GARD®skin.
Read more about the collaboration |
|
|
|
ExxonMobil The recently published article by ExxonMobil focuses on the challenges of determining skin sensitization hazard in the case of difficult-to-test substances with conflicting or low-confidence data, where GARD®skin data on UVCBs and hydrophobic substances provides valuable input for the integrated hazard assessment.
The article provides new peer-reviewed evidence for the applicability domain of GARD®skin on UVCBs, hydrophobic and highly complex substances.
Read the full article |
|
|
|
Our collaborations with industry partners led to the development of exciting projects and the generation of new scientific data. Throughout the year, the broad applicability of the GARD® assays was showcased in various posters and presentations.
|
|
|
|
We are expanding our distributor network to meet the increasing demand for in vitro toxicology and our innovative GARD® test portfolio. Collaborations with specialist CROs develop access to our services. We are excited to welcome GV Research Platform (GVRP) in India and Oroxcell in France as our latest partners. |
|
|
|
With a remarkable 1433% growth rate over the last four years, SenzaGen ranks 18th on Deloitte's Sweden Technology Fast 50, a testament to our pioneering work in technology and innovation.
Find out more about the award |
|
|
|
|